Development of a silica-based therapeutic vector to increase the efficacy and reduce the toxicity of certain drugs used to treat cancer.
Pharma In Silica inc.
6 enregistrements totalisant 404,117.00 $ CAN, selon les données ouvertes officielles du gouvernement du Canada.
Intégrer ce graphique
Par ministère
| Conseil national de recherches Canada | $404,117 | 6 enregistrements |
Enregistrements
As part of the development of a therapeutic nano-vecteur for the improvement of chemotherapy, development of laboratory validation tests to evaluate the physicochemical behaviour of this nano-vecteur...
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small and medium-sized enterprises that are unable to access existing COVID-19 business support.
Improvement of a silica-based therapeutic vector to increase the retention of the active within the nanovector and prevent premature release during all stages of manufacturing.
The funding provided by the IAP program is intended to assist innovative small and medium-sized enterprises in the start-up phase that cannot access existing commercial support related to COVID-19.
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.